Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07720271 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

AMAZE 9: A Research Study Investigating How Well Zenagamtide Tablets Help People With Excess Body Weight Lose Weight

Study acronym: AMAZE 9
StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Recruitment opened Show 4 more changesShow less
    • Lead sponsor: Novo Nordisk A/S to Novo Nordisk A/S
    • Trial sites expanded: 37 → 41 locations
    • Start date changed from estimate of Sep 1, 2026 to Aug 31, 2026
    • Eligibility criteria expanded, about 5 words
  2. Trial sites reduced: 42 → 37 locationsv3
  3. Re-verified, no change to tracked fieldsv2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Novo Nordisk
268 trials monitored
See 15 trials at risk
Obesity
3,874 trials monitored
See 152 trials at risk
The purpose of this clinical study is to find out if zenagamtide is safe and effective for treating people who have excess body weight. There are 2 study treatments in this study taken as oral tablets once a day. Participants will either get zenagamtide (the treatment being tested) or Placebo (treatment that has no active medicine in it). Which treatment participants get is decided by chance.
Trial Details
NCT Number NCT07720271
Lead Sponsor Novo Nordisk A/S
Conditions
(from sponsor)		 Overweight, Obesity
Related terms Obesity, Overweight
Enrollment 950 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov